D-dimer testing for recurrent VTE risk stratification
| . | Population . | N . | D-dimer assay . | Cutoff values . | VTE recurrence rate after stopping anticoagulation (per year) . | |
|---|---|---|---|---|---|---|
| Negative D-dimer . | Positive D-dimer . | |||||
| PROLONG3,4 | First unprovoked VTE | 608 | Clearview Simplify (whole blood; qualitative) | Positive | Overall: 4.4% (1st year) 0.4% (women, age <65) 6.7% (women, age >65) 5.1% (men, age <65) 8.2% (men, age >65) | Overall: 10.9% 5.4% (women, age <65) 8.9% (women, age >65) 12.9% (men, age <65) 11.8% (men, age >65) |
| DULCIS5 | First unprovoked VTE or VTE with minor risk factors | 1010 | 5 quantitative assays | Predefined age- and sex-specific values | Overall: 3.0% (median 1.93 years) 2.1% (age ≤70) 8.9% (age >70) 4.7% (men) 4.8% (women) | Overall: 8.8% 14.3% (age ≤70) 12.5% (age >70) 10.0% (men) 20.5% (women) |
| DODS6 | First unprovoked VTE | 410 | Clearview Simplify® (whole blood; qualitative) | Positive | Overall: 6.6% (1st year) 9.7% (men) 5.4% (women, non-estrogen) 0% (women, estrogen) | —- |
| DODS extended follow-up7 | First unprovoked VTE | 293 | Clearview Simplify® (whole blood; qualitative) | Positive | Overall: 5.1% (median 5 years) 7.5% (men) 3.8% (women, non-estrogen) 0.4% (women, estrogen) | —- |
| . | Population . | N . | D-dimer assay . | Cutoff values . | VTE recurrence rate after stopping anticoagulation (per year) . | |
|---|---|---|---|---|---|---|
| Negative D-dimer . | Positive D-dimer . | |||||
| PROLONG3,4 | First unprovoked VTE | 608 | Clearview Simplify (whole blood; qualitative) | Positive | Overall: 4.4% (1st year) 0.4% (women, age <65) 6.7% (women, age >65) 5.1% (men, age <65) 8.2% (men, age >65) | Overall: 10.9% 5.4% (women, age <65) 8.9% (women, age >65) 12.9% (men, age <65) 11.8% (men, age >65) |
| DULCIS5 | First unprovoked VTE or VTE with minor risk factors | 1010 | 5 quantitative assays | Predefined age- and sex-specific values | Overall: 3.0% (median 1.93 years) 2.1% (age ≤70) 8.9% (age >70) 4.7% (men) 4.8% (women) | Overall: 8.8% 14.3% (age ≤70) 12.5% (age >70) 10.0% (men) 20.5% (women) |
| DODS6 | First unprovoked VTE | 410 | Clearview Simplify® (whole blood; qualitative) | Positive | Overall: 6.6% (1st year) 9.7% (men) 5.4% (women, non-estrogen) 0% (women, estrogen) | —- |
| DODS extended follow-up7 | First unprovoked VTE | 293 | Clearview Simplify® (whole blood; qualitative) | Positive | Overall: 5.1% (median 5 years) 7.5% (men) 3.8% (women, non-estrogen) 0.4% (women, estrogen) | —- |
VTE, venous thromboembolism.